151 related articles for article (PubMed ID: 20150371)
1. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
[TBL] [Abstract][Full Text] [Related]
5. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Nghiemphu PL; Lai A; Green RM; Reardon DA; Cloughesy T
J Neurooncol; 2012 Nov; 110(2):245-50. PubMed ID: 22918789
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Broniscer A; Baker SJ; Stewart CF; Merchant TE; Laningham FH; Schaiquevich P; Kocak M; Morris EB; Endersby R; Ellison DW; Gajjar A
Clin Cancer Res; 2009 Jan; 15(2):701-7. PubMed ID: 19147777
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
10. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Kesavabhotla K; Schlaff CD; Shin B; Mubita L; Kaplan R; Tsiouris AJ; Pannullo SC; Christos P; Lavi E; Scheff R; Boockvar JA
J Exp Ther Oncol; 2012; 10(1):71-81. PubMed ID: 22946346
[TBL] [Abstract][Full Text] [Related]
16. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
Chang SM; Kuhn J; Wen P; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; Cloughesy T; De Angelis L; Razier J; Hess K; Dancey J; Prados MD;
Invest New Drugs; 2004 Nov; 22(4):427-35. PubMed ID: 15292713
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Yung WK; Vredenburgh JJ; Cloughesy TF; Nghiemphu P; Klencke B; Gilbert MR; Reardon DA; Prados MD
Neuro Oncol; 2010 Oct; 12(10):1061-70. PubMed ID: 20615922
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
